Janet M. Bruner
University of Texas MD Anderson Cancer Center
161 Papers
2.7K Citations
Janet M. Bruner is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Glioma & Medicine. The author has an hindex of 53, co-authored 160 publications. Previous affiliations of Janet M. Bruner include University of California, Berkeley & Ohio State University.
Chat about Author
Papers
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
W. K. A. Yung,Robert E. Albright,Jeffrey J. Olson,R Fredericks,Karen Fink,Michael D. Prados,Michael Brada,Alexander M. Spence,Raymond J. Hohl,William R. Shapiro,Michael Glantz,Harry S. Greenberg,Robert G. Selker,Nicholas A. Vick,R. Rampling,Henry S. Friedman,Peter C. Phillips,Janet M. Bruner,N. Yue,David Osoba,S Zaknoen,Victor A. Levin +21 more
TL;DR: Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 months in the PCB group, and freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received.
Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse
W. K. Alfred Yung,M. Prados,Ricardo Yaya-Tur,Steven S. Rosenfeld,Michael Brada,Henry S. Friedman,Robert Albright,Jeffrey Olson,Susan M. Chang,Alison M. O'Neill,Allan H. Friedman,Janet M. Bruner,Nancy Yue,Margaret Dugan,Sara L. Zaknoen,Victor A. Levin +15 more
TL;DR: Temozolomide demonstrated good single-agent activity, an acceptable safety profile, and documented HQL benefits in patients with recurrent AA, and maintenance of progression-free status and objectively assessed response were both associated with health-related quality of life (HQL) benefits.
Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994.
Tanya S. Surawicz,Bridget J. McCarthy,Varant Kupelian,Patti J. Jukich,Janet M. Bruner,Faith G. Davis +5 more
TL;DR: This study represents the largest compilation of data on primary brain and CNS tumors in the United States and noted higher occurrence rates in whites than in blacks for the following histologies: diffuse astrocytomas, anaplastic astro Cycles, glioblastomas, oligodendrogliomas, ependymomas, mixed gliomas, astroCytomas NOS, medulloblastoma, nerve sheath tumors, hemangiobasts, and germ
473
Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype.
Konrad Gabrusiewicz,Benjamin Rodriguez,Jun Wei,Yuuri Hashimoto,Luke M. Healy,Sourindra Maiti,Ginu Thomas,Shouhao Zhou,Qianghu Wang,Ahmed Elakkad,Brandon D. Liebelt,Nasser K. Yaghi,Ravesanker Ezhilarasan,Neal Huang,Jeffrey S. Weinberg,Sujit S. Prabhu,Ganesh Rao,Raymond Sawaya,Lauren A. Langford,Janet M. Bruner,Gregory N. Fuller,Amit Bar-Or,Wei Li,Rivka R. Colen,Michael A. Curran,Krishna P. Bhat,Jack P. Antel,Laurence J.N. Cooper,Erik P. Sulman,Amy B. Heimberger +29 more
TL;DR: G GAM profiling using flow cytometry studies revealed a continuum between the M1- and M2-like phenotype, and contrary to current dogma, GAMs exhibited distinct immunological functions, with the former aligned close to nonpolarized M0 macrophages.
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
Michael Brada,Khê Hoang-Xuan,R. Rampling,Pierre Yves Dietrich,Luc Dirix,David R. Macdonald,J. J. Heimans,B. A. Zonnenberg,Jose Bravo-Marques,Roger Henriksson,Roger Stupp,N. Yue,Janet M. Bruner,M. Dugan,S. Rao,Sara L. Zaknoen +15 more
TL;DR: Temozolomide demonstrated modest clinical efficacy, with an acceptable safety profile and measurable improvement in quality of life in patients with recurrent GBM, and should be explored further in an adjuvant setting and in combination with other agents.
401